[{"id":"cb11626b-0801-40b0-ae65-d3f235f68f1d","acronym":"Iintune-1","url":"https://clinicaltrials.gov/study/NCT04420884","created_at":"2021-01-18T21:18:09.463Z","updated_at":"2025-02-25T15:18:40.036Z","phase":"Phase 1/2","brief_title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04420884 - Iintune-1","lead_sponsor":"Takeda","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2026","study_completion_date":" 01/15/2026","last_update_posted":"2025-02-12"},{"id":"fab7c1a5-865b-44d1-9464-2b668a7a8d95","acronym":"","url":"https://clinicaltrials.gov/study/NCT06626633","created_at":"2025-02-26T15:02:37.996Z","updated_at":"2025-02-26T15:02:37.996Z","phase":"Phase 1","brief_title":"2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML","source_id_and_acronym":"NCT06626633","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-10-04"},{"id":"02e7dd18-d658-4ef3-b1a4-9d2da53c05e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846659","created_at":"2023-05-06T14:04:14.307Z","updated_at":"2024-07-02T16:34:36.888Z","phase":"Phase 2","brief_title":"Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies","source_id_and_acronym":"NCT05846659","lead_sponsor":"ImmuneSensor Therapeutics Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2023","start_date":" 07/07/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-10"},{"id":"6e2cb829-614d-4b97-bf37-e5a6143aeb0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05842785","created_at":"2023-05-06T15:04:03.887Z","updated_at":"2024-07-02T16:35:09.249Z","phase":"Phase 1/2","brief_title":"TSN222 in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05842785","lead_sponsor":"Tyligand Bioscience (Shanghai) Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSN222"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-17"},{"id":"e4e5b5ae-4209-402e-817d-04b5df309c96","acronym":"ON-5001","url":"https://clinicaltrials.gov/study/NCT06022029","created_at":"2023-09-01T17:11:43.841Z","updated_at":"2024-07-02T16:35:12.473Z","phase":"Phase 1","brief_title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","source_id_and_acronym":"NCT06022029 - ON-5001","lead_sponsor":"OncoNano Medicine, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ONM-501"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 08/29/2026","study_completion_date":" 08/29/2026","last_update_posted":"2024-03-28"},{"id":"444f47db-cfc2-467e-844b-6c0f5568dcc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04096638","created_at":"2021-01-18T20:02:44.860Z","updated_at":"2024-07-02T16:35:16.277Z","phase":"Phase 1","brief_title":"Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04096638","lead_sponsor":"invoX Pharma Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • SB 11285"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-03-06"},{"id":"28335d77-d098-4529-a1f0-51404005b2f4","acronym":"MK-1454-001","url":"https://clinicaltrials.gov/study/NCT03010176","created_at":"2021-01-29T07:13:56.449Z","updated_at":"2024-07-02T16:35:17.664Z","phase":"Phase 1","brief_title":"Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)","source_id_and_acronym":"NCT03010176 - MK-1454-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ulevostinag (MK-1454)"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 02/03/2017","start_date":" 02/03/2017","primary_txt":" Primary completion: 04/21/2022","primary_completion_date":" 04/21/2022","study_txt":" Completion: 04/21/2022","study_completion_date":" 04/21/2022","last_update_posted":"2024-02-26"},{"id":"a94bcbe4-e3f2-4d93-8686-baa0f53394db","acronym":"MK-1454-002","url":"https://clinicaltrials.gov/study/NCT04220866","created_at":"2021-01-18T20:32:40.942Z","updated_at":"2024-07-02T16:35:31.362Z","phase":"Phase 2","brief_title":"Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)","source_id_and_acronym":"NCT04220866 - MK-1454-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ulevostinag (MK-1454)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2023-10-27"},{"id":"0a8b544d-5385-4b08-8266-87f1c34ba6c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020185","created_at":"2021-01-18T19:44:10.860Z","updated_at":"2024-07-02T16:35:33.960Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of IMSA101 in Refractory Malignancies","source_id_and_acronym":"NCT04020185","lead_sponsor":"ImmuneSensor Therapeutics Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" HR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMSA101"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2023-10-11"},{"id":"64bcff1a-9d20-4e04-9f94-a4766a342655","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062602","created_at":"2023-10-02T20:12:31.941Z","updated_at":"2025-02-25T14:52:38.229Z","phase":"Phase 1","brief_title":"PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC","source_id_and_acronym":"NCT06062602","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CASP3 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CASP3 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-10-06"},{"id":"902fa0f5-f66c-4ff7-8f26-b928d9d04236","acronym":"MK-2118-001","url":"https://clinicaltrials.gov/study/NCT03249792","created_at":"2021-01-29T07:15:19.617Z","updated_at":"2024-07-02T16:35:52.271Z","phase":"Phase 1","brief_title":"Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)","source_id_and_acronym":"NCT03249792 - MK-2118-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-2118"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2023-03-27"},{"id":"1bdd6f63-5019-4415-8262-b36f6b64000b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592484","created_at":"2021-01-19T20:28:45.384Z","updated_at":"2024-07-02T16:35:56.190Z","phase":"Phase 1/2","brief_title":"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors","source_id_and_acronym":"NCT04592484","lead_sponsor":"Codiak BioSciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exoSTING"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 08/03/2022","primary_completion_date":" 08/03/2022","study_txt":" Completion: 12/23/2022","study_completion_date":" 12/23/2022","last_update_posted":"2023-02-08"}]